Treatment of NMOSD During Pregnancy in Women of Reproductive Age
Clinical Scenario
This protocol is for female patients of reproductive age with NMOSD who are pregnant or planning a pregnancy — a population in which both disease management and gestational safety must be carefully weighed together.
Key Considerations
Early counselling on family planning is a central priority in this group. Patients need to understand the risks and benefits associated with both pregnancy itself and the immunotherapies that may be required during pregnancy.
Treatment Approach (Partial Overview)
Management of NMOSD attacks occurring during pregnancy involves glucocorticoid therapy and apheresis-based strategies. The selection between available options is guided by clinical factors specific to each presentation.
Full regimen details, selection criteria, and sequencing are available in the complete structured protocol →
References
DOI: 10.1007/s00415-024-12288-2
- Female patients of reproductive age with AQP4-IgG-positive NMOSD must be counseled early on regarding family planning options and the risks and benefits of both pregnancy and immunotherapies during pregnancy.
- Treatment options for attacks during pregnancy include high-dose glucocorticoids and apheresis therapy (preferably with IA).
- The choice of treatment will depend on the severity of the attack and the stage of gestation.
View source ↗